Book contents
- Frontmatter
- Preface
- Contents
- CME Information
- Objectives
- Chapter 1 Neurobiology of Depression
- Chapter 2 Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
- Chapter 3 Norepinephrine and Dopamine Reuptake Inhibitors (NDRIs) and Selective Norepinephrine Reuptake Inhibitors (NRIs)
- Chapter 4 Alpha 2 Antagonists as Serotonin and Norepinephrine Disinhibitors (SNDIs) and Serotonin Antagonist/Reuptake Inhibitors (SARIs)
- Chapter 5 Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs)
- Chapter 6 Building a Treatment Plan with Novel Treatment and Augmentation Options For Depression
- Chapter 7 Depression in Women: Treating Symptoms Throughout the Life Span
- Chapter 8 Pharmacokinetics and Algorithms to Treat Depression
- Summary
- Abbreviations and Symbols
- Suggested Readings
- Index
- CME: Posttest
Summary
Published online by Cambridge University Press: 19 October 2021
- Frontmatter
- Preface
- Contents
- CME Information
- Objectives
- Chapter 1 Neurobiology of Depression
- Chapter 2 Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
- Chapter 3 Norepinephrine and Dopamine Reuptake Inhibitors (NDRIs) and Selective Norepinephrine Reuptake Inhibitors (NRIs)
- Chapter 4 Alpha 2 Antagonists as Serotonin and Norepinephrine Disinhibitors (SNDIs) and Serotonin Antagonist/Reuptake Inhibitors (SARIs)
- Chapter 5 Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs)
- Chapter 6 Building a Treatment Plan with Novel Treatment and Augmentation Options For Depression
- Chapter 7 Depression in Women: Treating Symptoms Throughout the Life Span
- Chapter 8 Pharmacokinetics and Algorithms to Treat Depression
- Summary
- Abbreviations and Symbols
- Suggested Readings
- Index
- CME: Posttest
Summary
• Three neurotransmitters involved in the regulation of depressive symptomatology were discussed: serotonin, norepinephrine and dopamine
• Circuits include pathways extensively traveled by 5HT, NE and DA
• Various genes are risk factors for depression
• Depression can often be treatment-resistant, resulting in the need for several different drug combinations prior to achieving response and full remission
• There are currently many classes of antidepressants available, with SSRIs, SNRIs and NDRIs most often considered first-line treatment options
• Augmentation of these first-line treatments can be selected by using a symptom-based strategy; that is, choose treatments most likely to reduce each individual patient's specific symptoms based upon the underlying neurobiological ratio-nale for these symptoms
• Several new treatments for depression are on the horizon
- Type
- Chapter
- Information
- Stahl's Illustrated Antidepressants , pp. 165Publisher: Cambridge University PressPrint publication year: 2009